Current Month
Article Features
  Breast Cancer Follow-Up Imaging Varies Widely
Breast Cancer Fueled by Mysterious Yin Yang Protein
Complementary Medicine for Cancer Can Decrease Survival
Curing Breast Cancer But At What Cost? Patients Report Heavy Financial Toll
Dense Breast Notification and Insurance Legislation Analysis
Effect of Acupuncture on Joint Pain Related to Aromatase Inhibitors Among Women with Early-Stage Breast Cancer
Extended Tamoxifen Therapy May Increase Risk of Endometrial Cancer
High Fruit and Vegetable Consumption May Reduce Risk of Breast Cancer
Massive Genomic Havoc in Breast Cancer is Revealed
Potential New Surgical Options for Women with Multiple Ipsilateral Breast Cancer
Promising Clinical Trial Results of Tucatinib with T-DM1 Against HER2+ Breast Cancer
Research Identifies New Breast Cancer Therapeutic Target
Scientists Discover a Dynamic Cellular Defense Against Breast Cancer Invasion
Scientists Discover a Mechanism of Drug Resistance in Breast and Ovarian Cancer
Surgeons Have Substantial Impact on Genetic Testing in Breast Cancer Patients Who Need It
Timing of Dinner May Affect Breast and Prostate Cancer Risk
Weight Loss Surgery May Affect the Risk of Cancer

Scientists Discover a Mechanism of Drug Resistance in Breast and Ovarian Cancer

There is a highly sophisticated way to treat some breast and ovarian cancers – a class of drugs called PARP inhibitors, designed to exploit the very defects that make tumors with certain mutations especially deadly. Yet this targeted approach to cancer therapy sometimes fails, and scientists have anxiously sought to understand why.

Now, researchers from The Rockefeller University offer insight into the biology behind this drug resistance and fresh hope for fighting it. Scientists in Titia de Lange’s lab and their colleagues have discovered the molecular means by which some cancers caused by errors in the gene BRCA1 evade treatment by drugs custom-tailored to kill them.

Described in the journal Nature, their work challenges previous assumptions about the mechanics by which these PARP inhibitors succeed or fail to help patients.

"This is a complete shift in our understanding of the mechanism that underlies this form of treatment for BRCA1 cancers," says de Lange.

Read More of the Main Article

Visit the Ezine

Visit the BreastCenter

Visit the Quality Corner
Avon Breast Cancer Crusade - AVON the company for women

  This website is supported in part by an unrestricted educational grant provided by Avon